How to Reconstitute Sermorelin + GHRP-6 Blend: Step-by-Step Lab Protocol
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
How to Reconstitute Sermorelin + GHRP-6 Blend: Step-by-Step Lab Protocol
The Sermorelin + GHRP-6 Blend (2mg/2mg per vial) combines Sermorelin — the 29-amino acid GHRH(1-29)NH2 GHRH-R reference agonist — with GHRP-6, a first-generation GHSR-1a agonist, co-lyophilised in a single 10mL sterile glass vial. This blend supports comparative GH axis pharmacology research using native-sequence GHRH analogue (sermorelin) paired with GHSR-1a activation, providing mechanistically authentic upstream GH axis dual-receptor stimulation data.
Materials Required
- Sermorelin + GHRP-6 Blend 2mg/2mg lyophilised vial
- Bacteriostatic water (BAC water) — 10mL vial
- 1mL sterile syringe with needle
- Alcohol swabs (70% isopropyl)
- Nitrile gloves
- Permanent marker for labelling
Pre-Reconstitution Preparation
Inspect the vial for intact lyophilised powder and unbroken seal. Allow to equilibrate to room temperature for 15 minutes. Both sermorelin and GHRP-6 are freely soluble in BAC water. The longer equilibration time for this blend (versus ipamorelin-based blends) accounts for sermorelin's larger molecular weight (MW 3357.9 g/mol) and 29-amino acid chain requiring slightly longer dissolution time.
Step-by-Step Reconstitution Protocol
Step 1 — Prepare workspace. Wipe work surface with 70% isopropyl alcohol. Allow to dry. Wear nitrile gloves.
Step 2 — Swab both stoppers. Clean rubber stoppers on both vials with separate fresh alcohol swabs. Air dry 10–15 seconds each.
Step 3 — Draw 2mL of BAC water. Draw 2mL of bacteriostatic water into a sterile syringe.
Step 4 — Inject slowly along the vial wall. Direct BAC water slowly down the inner glass wall of the blend vial over 15–20 seconds.
Step 5 — Dissolve by gentle swirling. Swirl gently for 30–60 seconds. The blend should dissolve to produce a clear, colourless solution. Sermorelin may require slightly more swirling than GHRP-6 — continue gently until fully clear. Do not shake or vortex.
Step 6 — Label. Record reconstitution date, concentrations (1mg/mL each), and initials.
Resulting Concentration
Adding 2mL BAC water to the 2mg/2mg blend vial yields 1mg/mL Sermorelin + 1mg/mL GHRP-6 (1000mcg/mL each). For comparative GHRH-R/GHSR-1a synergy studies, working concentrations of 1nM–100nM of each peptide are prepared by serial dilution into assay buffer or serum-free media.
Concentration Reference Table
| BAC Water Added | Sermorelin | GHRP-6 |
|---|---|---|
| 1mL | 2.0mg/mL | 2.0mg/mL |
| 2mL | 1.0mg/mL | 1.0mg/mL |
Storage Conditions and Stability
Store lyophilised blend at −20°C prior to reconstitution. Once reconstituted, store at 2–8°C for up to 28 days. Note that sermorelin is susceptible to DPP-IV cleavage at the Ala8 position in serum-containing media — for assays requiring stable GH axis stimulation over extended periods, include a DPP-IV inhibitor (sitagliptin 10µM or diprotin A 100µM) in the assay media to preserve sermorelin's GHRH-R activity throughout the incubation. GHRP-6 has some protease resistance and maintains activity under standard cell culture conditions. Do not freeze reconstituted solution.
Troubleshooting Common Reconstitution Issues
Powder not dissolving: Gently tilt and swirl to bring undissolved powder into contact with solvent. Do not heat. If incomplete after 60 seconds, inspect for moisture ingress or compromised seal.
Cloudy solution: Cloudiness may indicate aggregation or contamination. Discard if cloudiness persists after gentle swirling.
Foaming: Allow to settle naturally. Reduce injection speed on subsequent attempts and ensure stream is directed along the glass wall.
Loss of material: Swirl to contact all inner surfaces. Invert and draw from the stopper end for maximum recovery.
Research Application Notes
The Sermorelin + GHRP-6 blend provides the native GHRH sequence context (sermorelin = GHRH(1-29)) paired with first-generation GHSR-1a activation, making it the most pharmacologically authentic dual GH axis blend for research comparing native-like GHRH-R pharmacology against the CJC-1295-based blends that use stabilised GHRH analogues. In comparative studies between Sermorelin + GHRP-6 and CJC-1295 No DAC + GHRP-6 in matched GH3 pituitary cell preparations, the GHRH-R cAMP response will typically be lower for the sermorelin-based blend due to DPP-IV degradation of sermorelin in serum-containing media — this is actually the intended experimental comparison, demonstrating the functional pharmacokinetic advantage of CJC-1295 No DAC stabilisation. Sermorelin + GHRP-6 Blend 2mg/2mg vials are available from Pinnacle Peptides, verified at ≥99% purity by HPLC and mass spectrometry.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
